This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0009922808326085v1 48/2/161    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cathcart, S. Articles by Morrell, D. S. Search for Related Content PubMed PubMed Citation Articles by Cathcart, S. Articles by Morrell, D. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CANTHARIDINE Social Bookmarking                         What's this?

Parental Satisfaction, Efficacy, and Adverse Events in 54 Patients Treated With Cantharidin for Molluscum Contagiosum Infection

^* To whom correspondence should be addressed. E-mail: shelley.cathcart{at}gmail.com.

	Abstract

Objective To study the efficacy, tolerability, and parental satisfaction of cantharidin in a patient population at a pediatric dermatology referral center.

Methods Chart review was completed for 110 patients who presented with molluscum infection and were treated with cantharidin. A total of 54 were available for follow-up by telephone interview regarding adverse effects, parental satisfaction, and overall clearance of the infection.

Results Of those who were reachable, 96% improved after treatment with cantharidin. Parental satisfaction was 78%. Patients received an average of 2.2 treatments irrespective of outcome. Overall, 46% of patients experienced adverse events, including pain, pruritus, secondary infection, brisk immune response, and temporary hypopigmentation and 9% experienced an adverse event that they classified as severe.

Conclusions The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum. Compared with other treatments, it appears to be equally effective and well-tolerated and should be considered a potential frontline treatment.

First published on October 20, 2008, doi:10.1177/0009922808326085

Clinical Pediatrics 2009;48:161.

A more recent version of this article appeared on March 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?